TSX runs higher on rate cut expectations
On July 29, 2025, William Edward McKechnie, a director of Lexaria Bioscience Corp (NASDAQ: NASDAQ:LEXX), purchased 5,000 common shares of the company. The shares were bought at a price of $0.9063, totaling $4,531. The purchase comes as LEXX shares have declined over 75% in the past year, though InvestingPro analysis suggests the stock is currently undervalued. The micro-cap company, valued at approximately $18 million, maintains a strong balance sheet with more cash than debt.
Following the transaction, McKechnie directly owns 18,191 common shares of Lexaria Bioscience Corp. He also holds options for 63,000 common shares, at prices ranging from $0.87 to $3.39. While the company maintains a healthy current ratio of 3.9x, InvestingPro subscribers can access 8 additional key insights about LEXX’s financial health and growth prospects.
In other recent news, Lexaria Bioscience has been active with several key developments. The company announced interim results from its Phase 1b GLP-1-H24-4 study in Australia, focusing on its DehydraTECH-semaglutide and DehydraTECH-tirzepatide arms, alongside a Rybelsus control arm. In terms of analyst activity, H.C. Wainwright lowered its price target for Lexaria Bioscience to $4.00 from a previous $5.00, maintaining a Buy rating. This adjustment follows Lexaria’s report of positive partial results from a study comparing its oral DehydraTECH-liraglutide to the injected Saxenda.
Additionally, Lexaria Bioscience has expanded its patent portfolio to 50 with two new international patents, including one in Australia for treating epilepsy. The company has also reported advancements in its collaboration with a pharmaceutical company, PharmaCO, having completed initial pre-clinical studies under a Material Transfer Agreement. PharmaCO is interested in further data from Lexaria’s ongoing independent human study in Australia, which may lead to more collaborative efforts. Lexaria’s DehydraTECH technology has shown the capability to reduce side effects in GLP-1 drugs, addressing significant patient retention challenges in the sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.